Amicus Therapeutics (FOLD) Receivables (2016 - 2025)
Historic Receivables for Amicus Therapeutics (FOLD) over the last 14 years, with Q3 2025 value amounting to $113.8 million.
- Amicus Therapeutics' Receivables rose 1607.48% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 1607.48%. This contributed to the annual value of $101.1 million for FY2024, which is 1536.77% up from last year.
- As of Q3 2025, Amicus Therapeutics' Receivables stood at $113.8 million, which was up 1607.48% from $105.8 million recorded in Q2 2025.
- Amicus Therapeutics' 5-year Receivables high stood at $113.8 million for Q3 2025, and its period low was $44.9 million during Q1 2021.
- For the 5-year period, Amicus Therapeutics' Receivables averaged around $72.8 million, with its median value being $68.2 million (2023).
- As far as peak fluctuations go, Amicus Therapeutics' Receivables skyrocketed by 170.34% in 2022, and later surged by 4020.42% in 2023.
- Amicus Therapeutics' Receivables (Quarter) stood at $52.7 million in 2021, then grew by 25.68% to $66.2 million in 2022, then soared by 32.38% to $87.6 million in 2023, then grew by 15.37% to $101.1 million in 2024, then grew by 12.6% to $113.8 million in 2025.
- Its last three reported values are $113.8 million in Q3 2025, $105.8 million for Q2 2025, and $88.3 million during Q1 2025.